Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry)
- PMID: 29523557
- PMCID: PMC5844245
- DOI: 10.1136/bmj.k949
Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry)
Abstract
Objective: To determine outcomes and safety of endovascular treatment for acute ischaemic stroke, due to proximal intracranial vessel occlusion in the anterior circulation, in routine clinical practice.
Design: Ongoing, prospective, observational cohort study.
Setting: 16 centres that perform endovascular treatment in the Netherlands.
Participants: 1488 patients included in the Multicentre Randomised Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in the Netherlands (MR CLEAN) Registry who had received endovascular treatment, including stent retriever thrombectomy, aspiration, and all alternative methods for acute ischaemic stroke within 6.5 hours from onset of symptoms between March 2014 and June 2016.
Main outcome measures: The primary outcome was the modified Rankin Scale (mRS) score, ranging from 0 (no symptoms) to 6 (death) at 90 days after the onset of symptoms. Secondary outcomes were excellent functional outcome (mRS score 0-1), good functional outcome (mRS score 0-2), and favourable functional outcome (mRS score 0-3) at 90 days; score on the extended thrombolysis in cerebral infarction scale at the end of the intervention procedure; National Institutes of Health Stroke Scale score 24-48 hours after intervention; and complications that occurred during intervention, hospital admission, or three months' follow up period. Outcomes and safety variables in the MR CLEAN Registry were compared with the MR CLEAN trial intervention and control arms.
Results: A statistically significant shift was observed towards better functional outcome in patients in the MR CLEAN Registry compared with the MR CLEAN trial intervention arm (adjusted common odds ratio 1.30, 95% confidence interval 1.02 to 1.67) and the MR CLEAN trial control arm (1.85, 1.46 to 2.34). The reperfusion rate, with successful reperfusion defined as a score of 2B-3 on the extended thrombolysis in cerebral infarction score, was 58.7%, the same as for patients in the MR CLEAN trial. Duration from onset of stroke to start of endovascular treatment and from onset of stroke to successful reperfusion or last contrast bolus was one hour shorter for patients in the MR CLEAN Registry. Symptomatic intracranial haemorrhage occurred in 5.8% of patients in the MR CLEAN Registry compared with 7.7% in the MR CLEAN trial intervention arm and 6.4% in the MR CLEAN trial control arm.
Conclusion: In routine clinical practice, endovascular treatment for patients with acute ischaemic stroke is at least as effective and safe as in the setting of a randomised controlled trial.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BJE reports grants from Stryker Neurovascular and personal fees from Dekra and from Novartis, outside the submitted work. CBLMM reports grants from TWIN, during the conduct of the study and grants from CVON/Dutch Heart Foundation and from Stryker outside the submitted work (paid to institution). AAP reports personal fees from Bayer and from Siemens outside the submitted work. WHvZ reports personal fees from Codman and from Stryker outside the submitted work. RvdB reports a consultancy agreement with Codman Depuy outside the submitted work. HBW reports grants from the Dutch Heart Foundation outside the submitted work. AJY reports grants from Penumbra and Cerenovus/Neuravi and equity ownership interest from Insera Therapeutics outside the submitted work. AvdL reports consulting fees from Stryker outside the submitted work. DWJD reports grants from the Dutch Heart Foundation, AngioCare, Medtronic/Covidien/EV3, MEDAC/LAMEPRO, Penumbra, Top Medical/Concentric, and Stryker during conduct of the study; consultation fees from Stryker, Bracco Imaging, and Servier, received by the Erasmus University Medical Centre, outside the submitted work. All other authors did not receive support from any organisation for the submitted work, had no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, and had no other relationships or activities that could appear to have influenced the submitted work.
Figures
Similar articles
-
Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.Lancet. 2023 Apr 22;401(10385):1371-1380. doi: 10.1016/S0140-6736(23)00575-5. Epub 2023 Mar 29. Lancet. 2023. PMID: 37003289 Clinical Trial.
-
Endovascular Thrombectomy in Young Patients With Stroke: A MR CLEAN Registry Study.Stroke. 2022 Jan;53(1):34-42. doi: 10.1161/STROKEAHA.120.034033. Epub 2021 Dec 7. Stroke. 2022. PMID: 34872339 Clinical Trial.
-
White Matter Lesions and Outcomes After Endovascular Treatment for Acute Ischemic Stroke: MR CLEAN Registry Results.Stroke. 2021 Aug;52(9):2849-2857. doi: 10.1161/STROKEAHA.120.033334. Epub 2021 Jun 3. Stroke. 2021. PMID: 34078103 Free PMC article. Clinical Trial.
-
Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis.BMJ. 2016 Apr 18;353:i1754. doi: 10.1136/bmj.i1754. BMJ. 2016. PMID: 27091337 Free PMC article. Review.
-
Advances in endovascular treatment of acute ischaemic stroke.Intern Med J. 2015 Aug;45(8):798-805. doi: 10.1111/imj.12652. Intern Med J. 2015. PMID: 25443686 Review.
Cited by
-
Association of critical hypoperfusion biomarkers on CT with futile recanalization and poor outcome after mechanical thrombectomy in acute ischemic stroke.BMC Neurol. 2024 Oct 21;24(1):406. doi: 10.1186/s12883-024-03911-w. BMC Neurol. 2024. PMID: 39434001 Free PMC article.
-
Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial.JAMA. 2024 Sep 23;332(16):1355-66. doi: 10.1001/jama.2024.13933. Online ahead of print. JAMA. 2024. PMID: 39374319
-
Systems-level computational modeling in ischemic stroke: from cells to patients.Front Physiol. 2024 Jul 2;15:1394740. doi: 10.3389/fphys.2024.1394740. eCollection 2024. Front Physiol. 2024. PMID: 39015225 Free PMC article. Review.
-
The lesion core extent modulates the impact of early perfusion mismatch imaging on outcome variability after thrombectomy in stroke.Front Neurol. 2024 May 22;15:1366240. doi: 10.3389/fneur.2024.1366240. eCollection 2024. Front Neurol. 2024. PMID: 38841692 Free PMC article.
-
Thrombus Imaging Characteristics to Predict Early Recanalization in Anterior Circulation Large Vessel Occlusion Stroke.J Cardiovasc Dev Dis. 2024 Mar 29;11(4):107. doi: 10.3390/jcdd11040107. J Cardiovasc Dev Dis. 2024. PMID: 38667725 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical